Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer

NCT07867002 is registered in ClinicalTrials.gov with UNC Lineberger Comprehensive Cancer Center as lead sponsor.

NCT NCT07867002
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07867002 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Phase
Phase 3
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
October 31, 2032
Enrollment
140 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

endometrial adenocarcinoma, endometrial cancer, metastatic endometrial cancer, recurrent endometrial cancer, relapse endometrial cancer